Yüklüyor......

Intrinsic and Acquired Resistance to HER2-Targeted Therapies in HER2 Gene-Amplified Breast Cancer: Mechanisms and Clinical Implications

Approximately 25% of human breast cancers overexpress the HER2 (ErbB2) proto-oncogene, which confers a more aggressive tumor phenotype and associates with a poor prognosis in patients with this disease. Two approved therapies targeting HER2, the monoclonal antibody trastuzumab and the tyrosine kinas...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Rexer, Brent N., Arteaga, Carlos L.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2012
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3394454/
https://ncbi.nlm.nih.gov/pubmed/22471661
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!